Decreased interaction of raf-1 with its negative regulator spry2 as a mechanism for acquired drug resistance

Biomolecules and Therapeutics

Volumn 19, Issue 2, 2011, Pages 174-180

  Ahn, Jun Ho ^a   Kim, Yun Ki ^a   Lee, Michael ^a  

^a SolarLight Ltd   (South Korea)

Author keywords

Chemotherapy; MDR; Paclitaxel; Raf 1; Spry2

Indexed keywords

GLYCOPROTEIN P; PACLITAXEL; RAF PROTEIN; REGULATOR PROTEIN; SPROUTY 2 PROTEIN; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CANCER RESISTANCE; CELL NUCLEUS; CELL STRAIN 3T3; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DRUG SENSITIVITY; ENZYME ACTIVITY; FIBROBLAST; IC 50; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; STRAIN DIFFERENCE;

EID: 79956121823     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2011.19.2.174     Document Type: Article

References (31)

1. Abrams, S. L., Steelman, L. S., Shelton, J. G., Wong, E. W., Chap-pell, W. H., Basecke, J., Stivala, F., Donia, M., Nicoletti, F., Libra, M., Martelli, A. M. and McCubrey, J. A. (2010) The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 9, 1781-1791.
2. Ahn, J. H., Eum, K. H. and Lee, M. (2009) The enhancement of Raf-1 kinase activity by knockdown of Spry2 is associated with high sensitivity to paclitaxel in v-Ha-ras-transformed NIH 3T3 fibroblasts. Mol. Cell. Biochem. 332, 189-197.
3. Ahn, J. H., Eum, K. H. and Lee, M. (2010) Spry2 does not directly modulate Raf-1 kinase activity in v-Ha-ras-transformed NIH 3T3 fibroblasts. BMB Rep. 43, 205-211.
4. Blobe, G. C., Sachs, C. W., Khan, W. A., Fabbro, D., Stabel, S., Wetsel, W. C., Obeid, L. M., Fine, R. L. and Hannun, Y. A. (1993) Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional signifi cance of enhanced expression of PKC alpha. J. Biol. Chem. 268, 658-664.
5. Callaghan, R. and Higgins, C. F. (1995) Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br. J. Cancer 71, 294-299.
6. Chatterjee, D., Bai, Y., Wang, Z., Beach, S., Mott, S., Roy, R., Braastad, C., Sun, Y., Mukhopadhyay, A., Aggarwal, B. B., Darnowski, J., Pantazis, P., Wyche, J., Fu, Z., Kitagwa, Y., Keller, E. T., Sedivy, J. M. and Yeung, K. C. (2004) RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J. Biol. Chem. 279, 17515-17523.
7. Cornwell, M. M. and Smith, D. E. (1993) A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase. J. Biol. Chem. 268, 15347-15350.
8. Davis, J. M., Navolanic, P. M., Weinstein-Oppenheimer, C. R., Steelman, L. S., Hu, W., Konopleva, M., Blagosklonny, M. V., McCubrey, J. A. (2003) Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin. Cancer Res. 9, 1161-1170.
9. Dong, Y., Shao, S., Hu, J. and Yang, P. (2009) Reversal effect of Raf-1/ Mdr-1 siRNAs co-transfection on multidrug resistance in KBv200 cell line. Oral Oncol. 45, 991-997.
10. Gottesman, M. M. (2002) Mechanisms of cancer drug resistanace. Annu. Rev. Med. 53, 615-627.
11. Gupta, K. P., Ward, N. E., Gravitt, K. R., Bergman, P. J. and O'Brian, C. A. (1996) Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide. J. Biol. Chem. 271, 2102-2111.
12. Hacohen, N., Kramer, S., Sutherland, D., Hiromi, Y. and Krasnow, M. A. (1998) Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 92, 253-263.
13. Haldar, S., Chintapalli, J. and Croce, C. M. (1996) Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56, 1253-1255.
14. Jaffrezou, J. P., Herbert, J. M., Levade, T., Gau, M. N., Chatelain, P. and Laurent, G. (1991) Reversal of multidrug resistance by calcium channel blocker SR33557 without photoaffi nity labeling of P-glycoprotein. J. Biol. Chem. 266, 19858-19864.
15. Jazirehi, A. R., Vega, M. I., Chatterjee, D., Goodglick, L. and Bonavida, B. (2004) Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res. 64, 7117-7126.
16. Kim, S. H., SH, L., NH, K., CD, K. and BS, C. (1996) Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. Cancer Lett. 98, 199-205.
17. Lee, L. F., Haskill, J. S., Mukaida, N., Matsushima, K. and Ting, J. P. (1997) Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter. Mol. Cell. Biol. 17, 5097-5105.
18. Lee, M. (2006) Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2. Biochem. Biophys. Res. Commun. 350, 450-456.
19. Lee, M., Ahn, J. H. and Eum, K. H. (2009) The differences in biological properties between parental and v-Ha-ras transformed NIH3T3 cells. Cancer Res. Treat. 41, 93-99.
20. Lee, M., Koh, W. S. and Han, S. S. (2003) Down-regulation of Raf- 1 kinase is associated with paclitaxel resistance in human breast cancer MCF-7/Adr cells. Cancer Lett. 193, 57-64.
21. Marshall, M. S. (1995) Ras target proteins in eukaryotic cells. FASEB J. 9, 1311-1318.
22. McGrogan, B. T., Gilmartin, B., Carney, D. N. and McCann, A. (2008) Taxanes, microtubules and chemoresistant breast cancer. Biochim. Biophys. Acta 1785, 96-132.
23. Mercer, K. E. and Pritchard, C. A. (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim. Biophys. Acta 1653, 25-40.
24. Nobili, S., Landini, I., Giglioni, B. and Mini, E. (2006) Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets 7, 861-879.
25. Sasaki, A., Taketomi, T., Kato, R., Saeki, K., Nonami, A., Sasaki, M., Kuriyama, M., Saito, N., Shibuya, M. and Yoshimura, A. (2003) Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Nat. Cell Biol. 5, 427-432.
26. Weinstein-Oppenheimer, C. R., Henríquez-Roldán, C. F., Davis, J. M., Navolanic, P. M., Saleh, O. A., Steelman, L. S., Franklin, R. A., Robinson, P. J., McMahon, M. and McCubrey, J. A. (2001) Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin. Cancer Res. 7, 2898-2907.
27. Wu, C. P., Calcagno, A. M. and Ambudkar, S. V. (2008) Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr. Mol. Pharmacol. 1, 93-105.
28. Yeung, K., Seitz, T., Li, S., Janosch, P., McFerran, B., Kaiser, C., Fee, F., Katsanakis, K. D., Rose, D. W., Mischak, H., Sedivy, J. M. and Kolch, W. (1999) Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401, 173-177.
29. Yusa, K. and Tsuruo, T. (1989) Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specifi c sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 49, 5002-5006.
30. Yusoff, P., Lao, D. H., Ong, S. H., Wong, E. S., Lim, J., Lo, T. L., Leong, H. F., Fong, C. W. and Guy, G. R. (2002) Sprouty2 inhibits the Ras/MAP kinase pathway by inhibiting the activation of Raf. J. Biol. Chem. 277, 3195-3201.
31. Zhong, J., Troppmair, J. and Rapp, U. R. (2001) Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria. Oncogene 20, 4807-4816.